Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EPO Part B Claims Reimbursement To Follow Labeling On Dose Reduction

Executive Summary

The Centers for Medicare & Medicaid Services' final policy on Part B reimbursement for Amgen's Aranesp (darbepoetin alfa) and Epogen (epoeitin alfa) in end-stage renal disease follows product labeling recommendations that dosing be reduced when hematocrit levels reach a certain threshold
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS046547

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel